A case of treatment-related @entity2590 and XXXX following high-dose chemotherapy with autologous stem cell transplantation for @entity1893 .

@entity1 @entity7139 @entity417 @entity66 @entity2590 @entity3052 @entity1583 @entity1893 @entity2008 @entity3043 @entity6349
@entity2590 ( @entity2590 ) and @entity3052 (t-AML) are now well established as complications of cytotoxic chemotherapy. We experienced a 28-yr-old female @entity1 who developed @entity2590 with characteristic @entity2008 including 11q23 chromosomal rearrangement following high-dose chemotherapy with autologous stem cell transplantation (ASCT) for @entity1893 . The @entity1 was admitted with bulky abdominal masses of B cell lineage @entity1893 . After 2 cycles of systemic chemotherapy of the Vanderbilt regimen, the @entity1 underwent ASCT with high dose chemotherapy of the BEAC regimen. She also received radiation of 48 Gy for the residual periportal lymphadenopathy. The initial cytogenetic analysis of the infused mononuclear cells revealed a normal karyotype. Twenty two months after the ASCT, @entity3043 was noted and her bone marrow aspirate showed @entity6349 with myeloblasts up to 12% of nonerythroid nucleated cells. The @entity1 was diagnosed as @entity2590 ( @entity417 with an @entity7139 ). Cytogenetic analysis showed complex @entity2008 including 11q23 rearrangement, which is frequently found in topoisomerase II inhibitor-related @entity1583 . Four months later, it was noted that the @entity2590 had evolved into an overt t-AML. Cytogenetic analysis showed an evolving pattern with more @entity66 . The @entity1 was treated with combination chemotherapy, but her leukemic cells were resistant to the therapy.
